Navigation Links
Exelixis in Medical News

Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that that it will hold an analyst and investor briefing in conjunction with The American Society of Hematology 48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ET on Monday, December 10...

Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO

...d Analyst Briefing at ASCO, Monday, June 2, 6 pm exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... Ltd. (TSE: 4523.T) Encysive Pharmaceuticals Inc. (Nasdaq: ENCY ) Enzo Biochem Inc. (NYSE: ENZ ) ENZON PHARMACEUTICALS INC. (Nasdaq: ENZN ) exelixis Inc. (Nasdaq: EXEL ) Flamel Technologies (Nasdaq: FLML ) Illumina Inc. (Nasdaq: ILMN ) Incyte Corporation (Nasdaq: INCY ) Integra LifeScie...

Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference

...bcast and may be accessed in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About Exelixis Exelixis, Inc. is ...udes investigational compounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with major pharmaceutical and...

Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting

...rrently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb C...

Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone

...her investigating that potential in this trial." exelixis and Bristol-Myers Squibb established their joint L...l period of two years. The collaboration calls for exelixis and Bristol-Myers Squibb to jointly identify drug ...activities for such compounds. At time of signing, exelixis received a $17.5 million upfront payment and a com...

Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 18th Annual Healthcare Conference

... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Exelixis Announces October 10 Webcast of Presentation at the 2007 Bio InvestorForum Conference

... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference

... in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Exelixis Commences Public Offering of Common Stock

... effective automatic shelf registration statement. exelixis will also grant the underwriter a 30-day option to...nder the securities laws of any such state. About exelixis Exelixis, Inc. is a development-stage biotechnolo...he public offering. There can be no assurance that exelixis will complete the offering of the common stock on ...
Exelixis in Medical Technology

Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference

- Phase I data from XL880, Phase II data from XL999 studies scheduled for presentation during oral, poster sessions - SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that data from clinical trials of the company's investigational compounds XL880 and XL999...

Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia

...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...mstances on which any such statements are based. exelixis and the exelixis logo are registered U.S. trademarks. ...

Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO

...d Analyst Briefing at ASCO, Monday, June 2, 6 pm exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...

Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO

...Analyst Briefing at ASCO, Monday, June 2, 6 p.m. exelixis will host an investor and analyst briefing on Mond...ck Place (Regency C&D - 2nd Floor). At this event, exelixis will provide a review of its data presented at ASC...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...

Exelixis Announces First Quarter 2008 Financial Results

...7 and XL880*). * The technology transfer by exelixis to GlaxoSmithKline (GSK) in connection with GSK...ounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with...nces on which any such statements are based. exelixis and the...

GSK Does Not Option XL784 for Further Development

...784 for further development and commercialization. exelixis previously announced that XL784 failed to meet its...ns to choose XL784. As a result of GSK's decision, exelixis has the right to develop and commercialize XL784 e...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer

...s in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and...07 and Exelixis' other filings with the Securities and Exchange Commission. exelixis expressly disclaims any duty, obligation or undertaking to release publicly...

Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2

...rrently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb C...

Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference

... is the first small molecule compound developed by exelixis using its proprietary drug discovery engine. The c...active safety and pharmacokinetic profiles. About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...

Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer

...evelopment and commercialization agreement between exelixis and GlaxoSmithKline (GSK), GSK has the option, aft...a, gastric cancer and head and neck cancer. About exelixis Exelixis, Inc. is a development-stage biotechnolo...clinical development for cancer and renal disease. exelixis has established strategic corporate alliances with...
Exelixis in Biological Technology

REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO

Seven Abstracts Accepted for Presentation at ASCO SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) will hold an investor and analyst briefing in conjunction with the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) ...

Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting

Two oral presentations, two poster discussion presentations, three poster presentations SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that data from clinical trials of the company's investigational com...

Option to Develop Exelixis Compound Exercised By Genentech

SOUTH SAN FRANCISCO, Calif., March 14 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) today announced that Genentech, Inc. has exercised its option to further develop and commercialize Exelixis' compound XL518, a selective and potent inhibitor of MEK, which is currently in a phase 1 ...

Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day

SOUTH SAN FRANCISCO, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) announced today that it will hold its Third Annual R&D Day on Wednesday, December 5, 2007 from 10:00 a.m. ET / 7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT in New York. The company will discuss updat...

Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW ), and Exelixis Plant Sciences, a wholly owned subsidiary of Exelixis, Inc. (Nasdaq: EXEL ), announced today that the compani...

Sanofi-aventis Announces Second Quarter 2009 Results

... in triple negative breast cancer; license and collaboration agreement with exelixis Exploring external growth opportunities : significant boost to our ...r both of these products, which were developed by the biotechnology company exelixis SAR 407899, a rho-kinase inhibitor, entered Phase II in...

iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board

...is from 2001 until 2007, when the company merged with Evotec. He has advised numerous biotechnology companies, and co-founded two companies, including exelixis and Renovis. Dr. Goodman was a professor at Stanford University and the University of California, Berkeley for over two decades, and is curr...

Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration

... exelixis Generated 10 IND Compounds and Received over $235 ... will be limited to the compounds selected by GSK. exelixis will have the right to perform additional discover...ship of the compounds in our pipeline." To date, exelixis has received approximately $235 million from GSK, ...

Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference

...bcast and may be accessed in the Event Calendar page under Investors on the exelixis website at http://www.exelixis.com . About Exelixis Exelixis, Inc. is ...udes investigational compounds in phase 2 and phase 1 clinical development. exelixis has established strategic corporate alliances with major pharmaceutical and...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...APUTICS GROUP PLC (London Main Market, U.K.: AKT) exelixis INC. (NASDAQ: EXEL ) HUMAN GENOME SCIENCES INC. ...NYSE: CVD ) DAINIPPON SUMITOMO (Tokyo SE: 4506) exelixis INC (NASDAQ: EXEL ) FRESENIUS SE (Frankfurt, Ger...: BGC) COUGAR BIOTECHNOLOGY INC (NASDAQ: CGRB ) exelixis INC (NASDAQ: EXEL ) LIGAND PHARMACEUTICALS INC (...
Other Tags
(Date:7/30/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... iFitDress.com, a well-known wedding dress manufacturer and retailer, has unveiled ... from this, it has announced that all of them are ... of its old and new clients may now access the ... “We are pleased to release the new collection of satin ... of amazing items. It is true that our satin bridal ...
(Date:7/29/2014)... 2014 Dignity Sciences Limited, a privately ... a Phase I trial with DS107G, an oral formulation ... was a randomized, placebo-controlled, double-blind, single-ascending and multiple dose ... and effect of food on DS107G in healthy subjects. ... of DGLA following both single and multiple oral doses ...
(Date:7/29/2014)... discovered a chemical alteration in a single human gene ... studies, could give doctors a simple blood test to ... The discovery, described online in The American Journal ... involved in the function of the brain,s response to ... might otherwise be an unremarkable reaction to the strain ...
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps ... that he cured his condition with the use of this ... of his experience. , He claimed that he was ... just 4 days. Since his method turned out being so ... around the world. , The Nasal Polyps Treatment Miracle ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2
(Date:7/29/2014)... wrong food at a restaurant, don,t blame yourself; blame the ... with what you want and more to do with a ... the selections of over 300 diners, the Cornell study published ... showed that when it comes to what you order ... the menu and how you imagine it will taste. , ...
(Date:7/29/2014)... debilitating effects of a stroke is an immensely ... as well as effective therapy. Advancing such knowledge ... the primary focus of research by Sergei Adamovich, ... the NJIT faculty more than a decade ago. ... substantial funding from sources such as the National ...
(Date:7/29/2014)... developed an easier method to create DNAprotein conjugates. ... in diagnosing diseases. , DNA linked to proteins ... that can be used in diagnostic techniques, nanotechnology ... proteins with DNA can be used for ... of biological material. The method also provides easier ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
Other Contents